sellWeak cluster of 4
Samuel C. Blackman sold $29k of DAWN
HEAD OF R&D at Day One Biopharmaceuticals, Inc.. 2,206 shares at an average of $13.21, traded Nov 18, 2024, filed Nov 19, 2024.
Warning score
20Value
$29k
2,206 shares
Holdings after
1,064,015
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +5Trade size$29k at market
- 0Share of holdings soldSold 0.2% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027234, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | MOption exercise Common Stock | +1,187 | - | - | 1,058,722 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Common Stock | +1,437 | - | - | 1,060,159 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Common Stock | +6,062 | - | - | 1,066,221 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stock | -2,206 | $13.21 | $29k | 1,064,015 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Restricted Stock Unit (RSU)derivative | -1,187 | $0.00 | $0 | 4,756 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Restricted Stock Unit (RSU)derivative | -1,437 | $0.00 | $0 | 11,504 | Nov 19, 2024 |
| Nov 15, 2024 | MOption exercise Restricted Stock Unit (RSU)derivative | -6,062 | $0.00 | $0 | 72,752 | Nov 19, 2024 |
Related signals
Other insiders at Day One Biopharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $179k 15,459 shares | -7% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $70k 6,065 shares | -2% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Michael Vasconcelles Head of Research and Dev. | $32k 2,728 shares | -38% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $74k 6,395 shares | -8% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $67k 5,814 shares | -9% | |
| 36Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $142k 15,894 shares | -8% | |
| 28Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $36k 4,062 shares | -1% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $39k 4,319 shares | -6% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $33k 3,726 shares | -7% | |
| 35Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $109k 16,058 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.